HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Section

Policy

IRA, state PBM reform, Medicare, and regulatory action

BIO comes out swinging with 'Fight of Our Lives' campaign for the industry’s 50th birthday
PolicyFiercePharma ↗
The Biotechnology Innovation Organization has started the nationwide “​The Fight of Our Lives” campaign, creat…
Apr 17, 2026
Viatris and Teva Face Class II Recalls as FDA Keeps Pressure on Quality Standards
PolicyBriefing
Viatris pulled one lot of extended-release Xanax, and Teva recalled multiple lots of clonidine patches over co…
Apr 17, 2026
Pfizer rebuked by FDA for misleading Adcetris ads on Facebook
PolicyFiercePharma ↗
The FDA has scolded Pfizer over Facebook ads for the cancer drug Adcetris, accusing the Big Pharma of failing …
Apr 17, 2026
FDA's accelerated approval pathway needs stronger transparency, evidence standards: ICER
PolicyFiercePharma ↗
The FDA should strengthen the evidence required for drug approvals under its accelerated pathway, and increase…
Apr 17, 2026
Regulatory tracker: GSK's Blenrep gets all-clear in NICE final guidance
PolicyFiercePharma ↗
In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansion…
Apr 17, 2026
Teva scores in appeal as court revives $177M verdict against Lilly in migraine patent spat
PolicyFiercePharma ↗
The legal back-and-forth over migraine meds from Teva and Eli Lilly has resurfaced, with Teva gaining favor on…
Apr 17, 2026
← Newer Page 15 Older →
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.